JonesTrading Initiates Coverage On Decibel Therapeutics with Buy Rating, Announces Price Target of $25
JonesTrading initiates coverage on Decibel Therapeutics (NASDAQ:DBTX) with a Buy rating and announces Price Target of $25.
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has
HC Wainwright & Co. Initiates Coverage On Decibel Therapeutics with Buy Rating, Announces Price Target of $23
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Decibel Therapeutics (NASDAQ:DBTX) with a Buy rating and announces Price Target of $23.
SVB Leerink Maintains Outperform on Decibel Therapeutics, Lowers Price Target to $14
SVB Leerink analyst Mani Foroohar maintains Decibel Therapeutics (NASDAQ:DBTX) with a Outperform and lowers the price target from $15 to $14.
Watch Brilliant Earth, Landos Biopharma, Decibel Therapeutics Following TipRanks Article ‘3 “Strong Buy” Small-Cap Stocks With Plenty of Upside’
https://www.tipranks.com/news/article/159057-2
Baird Initiates Coverage On Decibel Therapeutics with Outperform Rating, Announces Price Target of $21
Baird analyst Jack Allen initiates coverage on Decibel Therapeutics (NASDAQ:DBTX) with a Outperform rating and announces Price Target of $21.
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid,
Decibel Therapeutics Announces Publication Of Foundational Study Of Noise-related Inner Ear Damage
Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from
Decibel Therapeutics’ Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ:DBTX) lead gene therapy product…
Decibel Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designations For DB-OTO For The Treatment Of Otoferlin-Related Congenital Hearing Loss
Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S.